210 related articles for article (PubMed ID: 30372027)
1. How Does Agonist and Antagonist Binding Lead to Different Conformational Ensemble Equilibria of the κ-Opioid Receptor: Insight from Long-Time Gaussian Accelerated Molecular Dynamics Simulation.
An X; Bai Q; Bing Z; Zhou S; Shi D; Liu H; Yao X
ACS Chem Neurosci; 2019 Mar; 10(3):1575-1584. PubMed ID: 30372027
[TBL] [Abstract][Full Text] [Related]
2. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
3. Molecular Interaction Between Butorphanol and κ-Opioid Receptor.
Ji J; Lin W; Vrudhula A; Xi J; Yeliseev A; Grothusen JR; Bu W; Liu R
Anesth Analg; 2020 Sep; 131(3):935-942. PubMed ID: 32701545
[TBL] [Abstract][Full Text] [Related]
4. Chemotype-selective modes of action of κ-opioid receptor agonists.
Vardy E; Mosier PD; Frankowski KJ; Wu H; Katritch V; Westkaemper RB; Aubé J; Stevens RC; Roth BL
J Biol Chem; 2013 Nov; 288(48):34470-83. PubMed ID: 24121503
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.
Zheng Z; Huang XP; Mangano TJ; Zou R; Chen X; Zaidi SA; Roth BL; Stevens RC; Katritch V
J Med Chem; 2017 Apr; 60(7):3070-3081. PubMed ID: 28339199
[TBL] [Abstract][Full Text] [Related]
6. Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes.
Leonis G; Avramopoulos A; Salmas RE; Durdagi S; Yurtsever M; Papadopoulos MG
J Chem Inf Model; 2014 Aug; 54(8):2294-308. PubMed ID: 25060329
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
Morgenweck J; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():600-9. PubMed ID: 26318102
[TBL] [Abstract][Full Text] [Related]
8. Docking and free energy perturbation studies of ligand binding in the kappa opioid receptor.
Goldfeld DA; Murphy R; Kim B; Wang L; Beuming T; Abel R; Friesner RA
J Phys Chem B; 2015 Jan; 119(3):824-35. PubMed ID: 25395044
[TBL] [Abstract][Full Text] [Related]
9. Structural Characterization of KOR Inactive and Active States for 3D Pharmacology and Drug Discovery.
Zaidi SA; Katritch V
Handb Exp Pharmacol; 2022; 271():41-64. PubMed ID: 33945028
[TBL] [Abstract][Full Text] [Related]
10. Revealing the Positive Binding Cooperativity Mechanism between the Orthosteric and the Allosteric Antagonists of CCR2 by Metadynamics and Gaussian Accelerated Molecular Dynamics Simulations.
An X; Bai Q; Bing Z; Liu H; Zhang Q; Liu H; Yao X
ACS Chem Neurosci; 2020 Feb; 11(4):628-637. PubMed ID: 31968162
[TBL] [Abstract][Full Text] [Related]
11. Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening.
Spetea M; Asim MF; Noha S; Wolber G; Schmidhammer H
Curr Pharm Des; 2013; 19(42):7362-72. PubMed ID: 23448472
[TBL] [Abstract][Full Text] [Related]
12. Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands.
Spetea M; Schmidhammer H
Handb Exp Pharmacol; 2022; 271():163-195. PubMed ID: 33454858
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
14. Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities.
Schmidhammer H; Erli F; Guerrieri E; Spetea M
Molecules; 2020 Nov; 25(21):. PubMed ID: 33147885
[TBL] [Abstract][Full Text] [Related]
15. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
[TBL] [Abstract][Full Text] [Related]
17. Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance.
Xu M; Petraschka M; McLaughlin JP; Westenbroek RE; Caron MG; Lefkowitz RJ; Czyzyk TA; Pintar JE; Terman GW; Chavkin C
J Neurosci; 2004 May; 24(19):4576-84. PubMed ID: 15140929
[TBL] [Abstract][Full Text] [Related]
18. Kinase cascades and ligand-directed signaling at the kappa opioid receptor.
Bruchas MR; Chavkin C
Psychopharmacology (Berl); 2010 Jun; 210(2):137-47. PubMed ID: 20401607
[TBL] [Abstract][Full Text] [Related]
19. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
20. Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor.
Che T; Majumdar S; Zaidi SA; Ondachi P; McCorvy JD; Wang S; Mosier PD; Uprety R; Vardy E; Krumm BE; Han GW; Lee MY; Pardon E; Steyaert J; Huang XP; Strachan RT; Tribo AR; Pasternak GW; Carroll FI; Stevens RC; Cherezov V; Katritch V; Wacker D; Roth BL
Cell; 2018 Jan; 172(1-2):55-67.e15. PubMed ID: 29307491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
